Case Study: QRM in Cleaning Validation
Scenario Overview
A pharmaceutical manufacturer operates a shared manufacturing train used for multiple oral solid dosage products.
Historically, cleaning validation was performed using a uniform approach:
identical sampling locations
identical acceptance strategies
similar validation protocols
consistent revalidation frequency
The approach appeared compliant and had passed previous inspections.
However, during expansion of the product portfolio, the site introduced a new compound with:
higher potency
lower therapeutic dose
increased toxicological concern
more difficult cleaning characteristics
The organization recognized that its existing validation strategy might no longer provide adequate assurance of contamination control.
A risk assessment was initiated to determine whether the current cleaning validation approach remained appropriate.
Initial Assumption
The site’s original assumption was:
Existing cleaning validation controls have always worked and should continue to be sufficient.
This assumption appeared reasonable because:
previous validation studies passed
environmental monitoring remained acceptable
no cleaning-related deviations had been reported
no contamination complaints had been received
However, the introduction of a higher-risk product changed the operating conditions.
The key question became:
Does historical success still justify confidence under the new conditions?
Risk Identification
The assessment team identified potential contamination-related failure modes.
Examples included:
| Potential Failure Mode | Potential Impact |
|---|---|
| Incomplete residue removal | Cross-contamination |
| Poor cleanability of equipment surfaces | Residue retention |
| Inadequate sampling locations | Undetected contamination |
| Ineffective cleaning parameters | Residual product carryover |
| Inappropriate acceptance limits | False confidence in cleaning effectiveness |
At this stage, no contamination had been detected.
The purpose was to identify where exposure could occur if existing controls proved insufficient.
Evaluating Severity
The team evaluated potential consequences associated with contamination failure.
Several factors increased severity:
higher compound potency
lower therapeutic dose
potential patient exposure
shared equipment usage
The assessment concluded that even small amounts of residual contamination could create meaningful quality concerns.
Severity increased significantly compared with products previously included in the validation program.
Evaluating Occurrence
Historical cleaning performance was reviewed.
The review identified:
successful historical cleaning validation
no known contamination events
acceptable routine monitoring results
However, the team also recognized an important limitation.
Historical performance involved different products with different risk profiles.
Past success did not automatically demonstrate future suitability.
Occurrence could not be evaluated solely through historical experience.
Evaluating Detectability
The assessment then focused on detectability.
Questions included:
Would existing sampling locations identify contamination reliably?
Could residue remain in difficult-to-clean areas?
Were analytical methods sensitive enough?
Would routine monitoring identify emerging issues?
The review identified several locations where residue accumulation was theoretically possible but not included in the existing validation protocols.
This finding increased concern.
As discussed in Detectability in QRM, confidence in controls depends partly on confidence in the ability to identify failure.
Reassessing Existing Controls
The assessment concluded that existing controls were not necessarily inadequate.
However, confidence in those controls was lower than originally assumed under the new operating conditions.
Several enhancements were recommended:
revised worst-case product selection
additional sampling locations
reassessment of acceptance limits
expanded analytical sensitivity evaluation
enhanced periodic review activities
The objective was not to react to a failure.
The objective was to address increased exposure before failure occurred.
Validation Strategy Changes
Based on the risk assessment, the organization implemented:
updated cleaning validation protocols
revised risk ranking of products
expanded sampling plans
enhanced residue recovery studies
revised revalidation triggers
The changes were proportional to the newly identified exposure.
Not every aspect of the program required redesign.
Only areas where risk understanding had changed were modified.
Outcome
Subsequent validation activities identified residue levels at one newly selected sampling location that had not previously been evaluated.
Although acceptance criteria were still met, the finding confirmed that the expanded risk assessment had improved visibility of potential contamination pathways.
No product impact occurred.
No deviation was generated.
The value of the assessment was preventive rather than corrective.
Lessons Learned
Several lessons emerged:
Historical success does not eliminate future risk.
Product changes may alter contamination exposure significantly.
Detectability strongly influences confidence in validation controls.
Sampling strategy affects visibility of contamination risk.
Risk assessments should evolve when operating conditions change.
Most importantly:
The organization strengthened contamination control before a failure occurred rather than after one was discovered.
What Good Looks Like
A mature cleaning validation risk assessment:
evaluates contamination pathways systematically
reassesses assumptions when products change
evaluates detectability realistically
aligns validation strategy with current exposure
updates controls when risk understanding evolves
Within Quality Risk Management (ICH Q9), validation decisions should reflect current operational conditions rather than historical success alone.
Operational Perspective
Many weaknesses in cleaning validation programs emerge not because organizations fail to perform validation studies, but because they continue relying on assumptions that were developed under different operating conditions.
As products, processes, and exposure profiles evolve, confidence in existing controls should be reassessed.
The strongest validation programs continuously evaluate whether historical validation conclusions remain justified by current operational reality.
Explore more on Quality Risk Management
Browse VerethiQ resources on risk identification, risk analysis, risk control, risk acceptance, risk communication, and risk review in GMP systems.
